Welcome to the inaugural episode of Workday Reimagined.

Hosted by Justin Williams (President & CRO, Accorio and former Workday VP), alongside Matt Harvison (Adaptive Planning), Brandon Britton (AI & Analytics), JB (Go-To-Market Strategy), and Eric Lachlan (Post-Production & AMS), this episode sets the stage for what’s ahead.

What we cover:
• Who this podcast is for — customers, partners, Workday admins, executives
• The dramatic shift toward AI and analytics in the Workday ecosystem
• What’s changed in customer expectations
• Why implementation alone isn’t enough
• The importance of transparency, realism, and raising standards
• What to expect from segments like Planning Pulse, Workday Intelligence, and In The Trenches

Workday isn’t just an HCM and Financials platform anymore — it’s positioning itself as an AI platform. That shift brings opportunity… and confusion.

This series is about cutting through the noise.

In Part 2 of our Life Sciences mini-series, Matt Harvison and Thomas Trammel shift focus from clinical trial cash burn to program and product-level cost forecasting.

They discuss how biotech organizations can model:

• Manufacturing costs by product

• Labor by shift and role

• Facility and overhead allocations

• Cost per unit trends

• What-if scenarios across headcount and volume

Learn how Workday Adaptive Planning enables life sciences teams to start simple and scale their forecasting sophistication over time, gaining visibility into margins before revenue even begins.

Clinical trial forecasting isn’t just a finance exercise, it’s a runway survival strategy.

In Episode 1 of our Life Sciences mini-series, Matt Harvison and Tom Trammel explore how Workday Adaptive Planning helps biotech and pre-revenue pharma teams plan clinical trials by phase, track burn rate, apply probability weighting, and run what-if scenarios when timelines shift.